Saudi hospital produces radiopharmaceuticals to diagnose breast, prostate cancer
A scientific team at the King Faisal Specialist Hospital and Research Center, for the first time in the region successfully produced radiopharmaceuticals called fluoroestradiol (FES) and F-PSMA with the use of the positron emission F-18 element that was produced through nuclear acceleration devices.
The scientific team said that these radiopharmaceuticals have been verified in terms of quality and efficiency for clinical use to diagnose breast and prostate cancers, stressing that they meet the high international standards for relevant institutions, such as the US Food and Drug Administration.
The hospital annually produces around 35,000 doses of radiopharmaceuticals that benefit nuclear medicine departments at Saudi hospitals in diagnosing several diseases and treating cancers.
